Oct 3 2007
Nanobac Pharmaceuticals Inc. is pleased to announce that its diagnostic test, NB2, being offered through an agreement with American Health Associates (AHA) will be available by late October. Parties interested in getting tested are encouraged to start the specimen collection process as AHA is ready to receive NB2 specimens.
“We are extremely excited to make our diagnostic test available to patients and physicians in the United States as we had discussed in our investor conference call,” stated Alex H. Edwards III, Director, Nanobac Pharmaceuticals. “This is the first step in creating awareness of the NB2 test's utility in the Diagnosis and Management of patients with a multitude of diseases, and is the start of acceptance as a standard of care in healthcare,” Edwards concluded.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. Information on how to obtain an NB2 test is available at www.nanobac.com .